Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-life use of delamanid: results from the European post-authorisation safety study.
Schönfeld N, Barkane L, Davoliene I, Danilovits M, Miliauskas S, Ader F, Kon OM, Lange C, Duvignaud A, Heiss-Neumann M, Hittel N, Lazarević N, Knebel I, Martin A, Eschenbach B, van Heumen E, George V. Schönfeld N, et al. Among authors: hittel n. IJTLD Open. 2024 Jun 1;1(6):274-278. doi: 10.5588/ijtldopen.24.0113. eCollection 2024 Jun. IJTLD Open. 2024. PMID: 39021446 Free PMC article.
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.
Gillespie SH, DiNardo AR, Georghiou SB, Sabiiti W, Kohli M, Panzner U, Kontsevaya I, Hittel N, Stuyver LJ, Tan JB, van Crevel R, Lange C, Thuong TNT, Heyckendorf J, Ruhwald M, Heinrich N. Gillespie SH, et al. Among authors: hittel n. Lancet Microbe. 2024 Sep;5(9):100869. doi: 10.1016/S2666-5247(24)00085-5. Epub 2024 May 9. Lancet Microbe. 2024. PMID: 38735303 Free article. Review.
Long-term safety and tolerability of delamanid-containing regimens in multidrug-resistant and extensively drug-resistant tuberculosis patients in a specialised treatment centre in Berlin, Germany.
Häcker B, Schönfeld N, Krieger D, Otto-Knapp R, Hittel N, Pflugmacher P, Bauer T. Häcker B, et al. Among authors: hittel n. Eur Respir J. 2020 Dec 3;56(6):2000009. doi: 10.1183/13993003.00009-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 32631834 Free article. No abstract available.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. von Groote-Bidlingmaier F, et al. Among authors: hittel n. Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7. Lancet Respir Med. 2019. PMID: 30630778 Clinical Trial.
23 results